NCT06207799View on ClinicalTrials.gov

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 17, 2024

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2031

Conditions
Multiple MyelomaPost-transplant MRD-guided Maintenance TherapyPre-transplant Purging
Interventions
DRUG

Elranatamab

Given by SC

DRUG

Lenalidomide

Given by PO

DRUG

Plerixafor

Given by SC

DRUG

Melphalan

Given by IV

DRUG

Busulfan

Given by PO

DRUG

G-CSF

Given by IV

PROCEDURE

Stem cell transplant

Given by IV

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER